Arrowstreet Capital
UNCY icon

Arrowstreet Capital’s Unicycive Therapeutics UNCY Stock Holding History

Arrowstreet Capital’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.26M Buy
+269,159
New +$1.4M ﹤0.01% 1520

Other funds holding UNCY

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Arrowstreet Capital's UNCY Position: Q3 2026 in Review

Arrowstreet Capital opened a new position in Unicycive Therapeutics (UNCY) in Q3 2026: 269,159 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #1520 among its holdings.

64 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • Arrowstreet Capital held 269,159 shares of Unicycive Therapeutics worth $1.26M as of Q3 2026.
  • Unicycive Therapeutics was a new Arrowstreet Capital position in Q3 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q3 2026, its #1520 holding.
  • 64 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.